[Anticoagulation instauration in device-detected subclinical atrial fibrillation: what impact does it have on outcomes?].
作者信息
Fuentes Blanco Hugo Fernando, Malagón Albarracín Diego Alejandro, González Perdomo Francisco Javier, Ortega Sierra Michael
机构信息
Departamento de Medicina, Universidad Del Magdalena, Santa Marta, Colombia. Universidad del Magdalena Departamento de Medicina Universidad Del Magdalena Santa Marta Colombia.
Departamento de Medicina, Universidad Militar Nueva Granada, Bogotá, Colombia. Universidad Militar Nueva Granada Departamento de Medicina Universidad Militar Nueva Granada Bogotá Colombia.
出版信息
Arch Peru Cardiol Cir Cardiovasc. 2024 Jun 24;5(2):e365. doi: 10.47487/apcyccv.v5i2.365.. eCollection 2024 Apr-Jun.
Abstract
摘要
相似文献
1
[Anticoagulation instauration in device-detected subclinical atrial fibrillation: what impact does it have on outcomes?].[设备检测到的亚临床房颤中的抗凝启动：对结局有何影响？]
Arch Peru Cardiol Cir Cardiovasc. 2024 Jun 24;5(2):e365. doi: 10.47487/apcyccv.v5i2.365.. eCollection 2024 Apr-Jun.
2
Rationale and Design of the Evaluation of Oral Anticoagulation for Reduction of Thrombo-embolism in Chinese Patients with Device-Detected Subclinical Atrial Fibrillation (ART-CAF) Trial: an Open-Label Registry-Based Clinical Trial.评估口服抗凝药减少中国经器械检测发现的无症状性心房颤动患者血栓栓塞事件（ART-CAF）试验的原理和设计：一项基于开放性登记的临床试验。
Cardiovasc Drugs Ther. 2018 Aug;32(4):389-396. doi: 10.1007/s10557-018-6807-9.
3
Thromboembolic risk and oral anticoagulation in subclinical atrial fibrillation.亚临床房颤的血栓栓塞风险与口服抗凝治疗
Trends Cardiovasc Med. 2025 Jan;35(1):1-7. doi: 10.1016/j.tcm.2024.04.001. Epub 2024 Apr 10.
4
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.直接口服抗凝剂预防器械检测到的心房颤动患者卒中：NOAH-AFNET 6 和 ARTESiA 试验的研究水平荟萃分析。
Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12.
5
Subclinical atrial fibrillation - what is the risk of stroke?亚临床房颤——中风风险有多大？
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun;163(2):107-113. doi: 10.5507/bp.2018.083. Epub 2019 Jan 10.
6
Physician decision making in anticoagulating atrial fibrillation: a prospective survey of a physician notification system for atrial fibrillation detected on cardiac implantable electronic devices of patients at increased risk of stroke.心房颤动抗凝治疗中的医生决策：一项针对在心脏植入式电子设备上检测到心房颤动的卒中高危患者的医生通知系统的前瞻性调查。
Ther Adv Cardiovasc Dis. 2018 Apr;12(4):113-122. doi: 10.1177/1753944717749739.
7
Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association.无症状性和器械检出性心房颤动：思考知识差距：美国心脏协会的科学声明。
Circulation. 2019 Dec 17;140(25):e944-e963. doi: 10.1161/CIR.0000000000000740. Epub 2019 Nov 7.
8
Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery.设备检测到的大型远程监测队列中的心房颤动：抗凝治疗的意义和新的服务提供途径的需求。
J Interv Card Electrophysiol. 2023 Oct;66(7):1659-1668. doi: 10.1007/s10840-023-01481-4. Epub 2023 Feb 3.
9
Physician decision making in anticoagulating atrial fibrillation: a prospective survey of a physician notification system for atrial fibrillation detected on cardiac implantable electronic devices of patients at increased risk of stroke.心房颤动抗凝治疗中的医生决策：一项针对在心脏植入式电子设备上检测到心房颤动的中风高危患者的医生通知系统的前瞻性调查。
Ther Adv Cardiovasc Dis. 2018 Jan 1:1753944718749739. doi: 10.1177/1753944718749739.
本文引用的文献
1
Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits.亚临床房颤与抗凝：权衡绝对风险与获益
Circulation. 2024 Mar 26;149(13):989-992. doi: 10.1161/CIRCULATIONAHA.123.067919. Epub 2024 Mar 25.
2
[Latin American research in heart failure: visual and bibliometric analysis of the last 20 years].[拉丁美洲心力衰竭研究：过去20年的可视化与文献计量分析]
Arch Peru Cardiol Cir Cardiovasc. 2023 Dec 27;4(4):141-150. doi: 10.47487/apcyccv.v4i4.328. eCollection 2023 Oct-Dec.
3
Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?心脏植入式电子设备检测无症状性心房颤动：NOAH 和 ARTESiA 试验后抗凝治疗的决策如何？
Eur J Intern Med. 2024 May;123:37-41. doi: 10.1016/j.ejim.2024.01.002. Epub 2024 Jan 27.
4
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.直接口服抗凝剂预防器械检测到的心房颤动患者卒中：NOAH-AFNET 6 和 ARTESiA 试验的研究水平荟萃分析。
Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12.
5
Subclinical Atrial Fibrillation: A Silent Threat with Uncertain Implications.亚临床房颤：一种具有不确定影响的隐匿性威胁。
Annu Rev Med. 2022 Jan 27;73:355-362. doi: 10.1146/annurev-med-042420-105906. Epub 2021 Nov 17.
6
Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association.无症状性和器械检出性心房颤动：思考知识差距：美国心脏协会的科学声明。
Circulation. 2019 Dec 17;140(25):e944-e963. doi: 10.1161/CIR.0000000000000740. Epub 2019 Nov 7.
7
Subclinical and Asymptomatic Atrial Fibrillation: Current Evidence and Unsolved Questions in Clinical Practice.亚临床和无症状心房颤动：临床实践中的当前证据和未解决问题。
Medicina (Kaunas). 2019 Aug 18;55(8):497. doi: 10.3390/medicina55080497.
8
Device-Detected Atrial Fibrillation.设备检测到的心房颤动。
Circulation. 2019 May 28;139(22):2513-2515. doi: 10.1161/CIRCULATIONAHA.119.040549. Epub 2019 Mar 17.
Zotero 插件